Moderna’s melanoma vaccine data bring adoption test into focus

Moderna's personalized cancer vaccine intismeran autogene combined with Keytruda reduced the risk of recurrence or death by 42% in a Phase III melanoma trial (HR=0.58, p<0.001), validating the benefit of personalized vaccines in adjuvant therapy. But the therapy faces challenges from personalized manufacturing complexity, high costs, and competition from neoadjuvant immunotherapy strategies; the trial did not directly compare against neoadjuvant immunotherapy regimens, so commercial adoption remains to be weighed.